Phase 2 N=150 Nitric Oxide Inhalation to Treat Sickle Cell Pain Crises
Anemia, Sickle Cell
Primary: Time to Vaso-occlusive Pain Crisis (VOC) Resolution — 61.83; 55.16 Hours — p== 0.8085
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=4 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
Phase 2 N=109 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
Anemia, Sickle Cell
Primary: Gardos Channel Activity — -0.0342; 0.0043; 0.1076 mmol/10^13 cells x min — p=0.080
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
Phase 2 N=29 Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Change in D-dimer — 478.8; 260.1 ng/mL
Phase 3 N=30 Stem Cell Transplantation for Sickle Cell Anemia
Sickle Cell Disease
Primary: Number of Participants With Graft Failure — 3 Participants
Phase 2 N=70 L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
Sickle Cell Anemia · Thalassemia
Primary: Number of Occurrences of Painful Sickle Cell Crises — 4.5; 10.8 Crisis — p=0.076
N/A N=483 Comparison of Patient Centered Outcomes for People With Sickle Cell Disease in the Acute Care Setting
Sickle Cell Disease
Primary: Time (Minutes) From Arrival to Center to Time First Dose of Parenteral Pain Medication Administered — 125.3; 61.8 minutes
Phase 2 N=108 Arginine Therapy for Sickle Cell Disease Pain
Sickle Cell Disease · Vaso-occlusive Pain Episode
Primary: Total Parenteral Opioid Use in IV Morphine Equivalents — 1.77; 1.95; 2.36 mg/Kg
Phase 2 N=198 Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises
Sickle Cell Disease
Primary: Annual Rate of Sickle Cell-related Pain Crises (SCPC) Per Hodges-Lehmann Median — 1.63; 2.01; 2.98 SCPC per year — p== 0.010
Phase 3 N=230 A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia
Sickle Cell Anemia · Sickle ß0-Thalassemia
Primary: The Number of Occurrences of Sickle Cell Crises — 3; 4 Number of crises — p=0.0052
Phase 2 N=96 A Phase II Trial of Regadenoson in Sickle Cell Anemia
Sickle Cell Anemia
Primary: Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More — 21; 10 Participants
Phase 3 N=208 Intravenous Magnesium for Sickle Cell Vasoocclusive Crisis
Sickle Cell Disease
Primary: Hospital Length of Stay (Hours) — 56; 47 hours — p=0.24
Phase 3 N=345 Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
Anemia, Sickle Cell
Primary: Time to Readiness for Discharge From Hospital — 87.78; 93.47 Hours — p=0.7944
Phase 1 N=39 Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT
N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Phase 4 N=106 Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease
Sickle Cell Disease
Primary: Difference in Pain Score as Measured by a Visual Analogue Scale (VAS) — 26.4; 43.0 Units on a 100 mm VAS — p=0.0311
Phase 3 N=40 Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally
Pain · Sickle Cell Disease
Primary: Acute Chest Syndrome — 2; 1 participants
Phase 2 N=37 Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease
Anemia, Sickle Cell
Primary: C-Reactive Protein — 11.4; 6.8 mg/l
Phase 4 N=140 An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
Sickle Cell Disease (SCD)
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) — 3; 3 Participants
N/A N=237 Preventing Acute Chest Syndrome by Transfusion Feasibility Study
Sickle Cell Disease
Primary: Acute Chest Syndrome — 11; 11; 22; 85 participants
Phase 2 N=30 Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
Phase 3 N=241 A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Sickle Cell Disease · Vaso-occlusive Pain Episode in Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Rate of Vaso-occlusive Crises (VOCs) [Adjudicated] Through Week 48 — 1.49; 1.58 Events per 48 weeks — p=0.6967
Phase 2 N=5 Nitrous Oxide Analgesia Vaso-occlusive Crisis
Sickle Cell Disease · Vaso-occlusive Crisis
Primary: Pain Score — 5.7 score on a scale
Phase 2 N=10 Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
Sickle Cell Disease
Primary: Fetal Hemoglobin Level — 8.3 Percentage
N/A N=212 Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease
Anemia, Sickle Cell
Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008
N/A N=67 Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: SCD-specific Knowledge — 32.0; 32.0; 33.5; 33 score on a scale
N/A N=120 Decision Aid for Therapeutic Options In Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia · Hemoglobin SS
Primary: Acceptability of Decision Aid Education Assessed by the Acceptability Survey — 3; 3; 3; 3 units on a scale
N/A N=278 Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients
Sickle Cell Crisis
Primary: Pain Scores — 5.6; 5.7 score on a scale
Phase 2 N=46 Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64